Cardiology

Most bleeding events in non-CVD patients are GI-related

(HealthDay)—Among a cohort of individuals without cardiovascular disease (CVD) not receiving antiplatelet therapy, most major bleeding events involved gastrointestinal bleeding and 7 percent of bleeding events were fatal, ...

Cardiology

Clotting time in transfemoral PCI linked to bleeding risk

(HealthDay)—Higher maximal activated clotting time (ACT) is associated with a greater risk of major bleeding after transfemoral (TF) percutaneous coronary intervention (PCI) than after transradial (TR) PCI, according to ...

Cardiology

Interruption of apixaban doesn't impact bleeding in A-fib

(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according ...

Cardiology

ORBIT bleeding risk score performs best in A-fib

(HealthDay)—Four contemporary clinical bleeding risk scores are able to identify atrial fibrillation (AF) patients at risk for major bleeding and life-threatening bleeding, according to a study published online Nov. 7 in ...

Cardiology

ACC guides treatment of bleeding with oral anticoagulation

(HealthDay)—A decision pathway has been developed to guide management of acute bleeding in patients treated with oral anticoagulants (OACs); the decision pathway was published online Dec. 1 in the Journal of the American ...

Cardiology

Is low-dose aspirin right for you after surgery?

(HealthDay)—Each year, millions of American heart patients go "under the knife" for various kinds of surgery. Often they're told to take a low-dose aspirin, to help lower their odds for a post-op blood clot.

Cardiology

Results from the DAPT STEMI trial reported

November 1, 2017 - The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months of ...

page 4 from 9